Navigation Links
Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., April 03, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic hormone-refractory prostate cancer (HRPC). Additional follow-up of the 22 patients who received the dose that is comparable to that being employed in the company's ongoing Phase 3 program indicates that the median survival is 35.0 months. Four patients have withdrawn consent to further follow-up and thus were censored in the analysis. The company previously reported final median survival results from its first multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer in 34 patients with metastatic HRPC that showed an overall median survival of 26.2 months. The survival results from the two, independent multi-center Phase 2 clinical trials compare favorably to the previously published median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Taxotere(R) (docetaxel) chemotherapy plus prednisone, the current standard of care for these patients. The company's ongoing Phase 3 program is designed to confirm this potential survival benefit for GVAX immunotherapy for prostate cancer.

"We are certainly encouraged by the survival data from the second Phase 2 trial of GVAX immunotherapy for prostate cancer. The final median survival of 35.0 months also compares favorably to a predicted median survival of 22.0 months for these 22 patients based on a validated, published nomogram using seven prognostic variables," stated Rob Dow, M.D., chief medical officer of Cell Genesys. "We continue to hope that GVAX immunotherapy for prostate cancer may some day offer a new treatment option for patients with this disease."

GVAX immunotherapy for prostate cancer is currently
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
2. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
11. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
Post Your Comments:
(Date:11/25/2008)...spondents against expanding statin use broadly in ...S, N.J., Nov. 25 JUPITER, a clinic...diovascular risk of healthy patients with elevated...der adults, according to a national poll directed ...ook part in the online poll conducted by medical n...
(Date:11/25/2008).... 25 Pharmacyclics, Inc....ny has completed a Phase 1,clinical trial with PC...l-molecule Factor VIIa inhibitor. The trial was co...luate the safety and pharmacologic effect of,PCI-...ed in a linear dose,response in the International...
(Date:11/24/2008)...SAKA, Japan, Nov. 24 Takeda Pharma...idiary, Takeda Global Research & Development C...tis Advisory Committee of the U.S. Food and Drug A...ve febuxostat for the treatment of hyperuricemia ...favor of approval, with one panel member abstainin...
(Date:11/24/2008)... Cancer Awareness Month , , Oak Brook, Ill.... Society for Gastrointestinal Endoscopy (ASGE) and...up this November to raise awareness about pancreat...d the resources that are available for them. , ...e of cancer deaths in the U.S. In 2008, an estimat...
Breaking Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 2ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 4ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 5ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 6New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 1New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 2New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 3New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 4History Making Obesity Awareness Event Scheduled to Take Place in Washington DC on June 17 2008 19035 1History Making Obesity Awareness Event Scheduled to Take Place in Washington DC on June 17 2008 19035 2Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 1Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 2Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 3Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 4Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 5Ancient protein offers clues to killer condition 3266 1Ancient protein offers clues to killer condition 3266 2
...720 Mechanisms in Multiple,Sclerosis May Include D... studies suggest FTY720 stimulates cells,that may ...f the,CNS affected by multiple sclerosis , ·...,sclerosis Phase II clinical study found that the ...s significantly lower in the,FTY720 groups compare...
...)--May 4, 2007 - New data from a,randomized, doubl...E(R) (glatiramer acetate injection) along with the... (Gd)-enhancing lesions,of the brain by 63 percent...ing multiple sclerosis (RRMS), as measured by,magn...ceiving,COPAXONE(R) alone. Additionally, the nine-...
Other Medicine Technology:Data to be presented at AAN Meeting -Study results of drug,candidate for MS 2Data to be presented at AAN Meeting -Study results of drug,candidate for MS 3Data to be presented at AAN Meeting -Study results of drug,candidate for MS 4Data to be presented at AAN Meeting -Study results of drug,candidate for MS 5Data to be presented at AAN Meeting -Study results of drug,candidate for MS 6Data to be presented at AAN Meeting -Study results of drug,candidate for MS 7Data to be presented at AAN Meeting -Study results of drug,candidate for MS 8Data to be presented at AAN Meeting -Study results of drug,candidate for MS 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
(Date:12/2/2008)...g Improves Service and Efficiency by Automating Ac...NGHAM, Mass., Dec. 2 Courion(R) C...liance, today announced that Brookdale Senior Livi...ior living communities, has deployed Courion,s Ent...ecure access to enterprise applications and other ...
(Date:12/2/2008)...rate With Traditional Holiday Cuisine , , M...inistries ( www.angelfoodministries.com ), an orga...at low-costs, to anyone who wishes to participate,... a specialty Christmas Box which includes everythi...ost sites are now taking orders throughout the cou...
(Date:12/2/2008)...and Professionals Shares Experience , Dealing w...ation, More , , WASHINGTON, Dec. 2 /PRNewsw...nal disability association working on equity, dive...cant disabilities announces the official launch of...ry accessible to people with disabilities, family ...
(Date:12/2/2008)...available to seniors , , DETROIT, Dec. 2 /P...P) is adding acupuncture and chiropractic services...re Advantage members beginning January 1, 2009. HA...ncourages Medicare beneficiaries to choose activit...ck in their wallets. , , HAP offers a Flex...
Breaking Medicine News(10 mins):Health News:Courion Helps Reduce Costs at Nation's Largest Operator of Senior Living Communities 2Health News:Courion Helps Reduce Costs at Nation's Largest Operator of Senior Living Communities 3Health News:Angel Food Ministries to Distribute Holiday Grocery Relief 2Health News:New Website Links People With Disabilities to Peers for Help 2Health News:HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 2Health News:HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 3
...ing weight by dietary changes and increased physic...condition where blood glucose// levels are higher ...ese are the results of a new study that was publis...Care, of women who participated in the Diabetes Pr...
...e being hit the most by obesity-related disorders....ne by doctors that fails to// detect these problem...ight divided by height- is used in the standard me...ing to the experts, East and South Asians were aff...
...n Canada ahead of HIV/AIDS, diabetes and car accid...inal communities. With World// Suicide Prevention ... from the Canadian Institutes of Health Research (...lenges posed by suicide, its causes and possible p...
...er a period of 30 years and has infected many peop...Recently, 3 people in Delhi// have tested positive...rs who transmit chikungunya fever to human. The N...able Diseases (NICD) tested 6 blood samples of whi...
Other Medicine News:Health News:Bladder Control following Weight loss in women with Prediabetes 2Health News:Bladder Control following Weight loss in women with Prediabetes 3Health News:Getting Serious About Suicide Prevention 2
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology.
Inquire
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of
Medicine Products: